CAS: 34642-77-8; Amoxicillin Sodium

上下游产品

CAS号26787-78-0 阿莫西林

阿莫西林 在 三乙胺,Sodium 2-Ethylhexanoic Acid体系中,用 甲醇,乙酸甲酯作为反应溶剂,以90%的收率获得amoxicillin Sodium
参考文献:[En] Improved Process For Preparing Amoxicillin Sodium[Fr] Pr°Cédé Amélioré Pour Préparer Du Sodium D'Amoxicilline
标题:[En] Improved Process For Preparing Amoxicillin Sodium[Fr] Pr°Cédé Amélioré Pour Préparer Du Sodium D'Amoxicilline
摘要:一种改进的制备无菌阿莫西林及其碱金属盐的方法,其中所述方法包括以下步骤:I) 在甲酸甲酯,甲醇和三乙胺中溶解阿莫西林三水合物;Ii) 将所得溶液通过一系列过滤器;Iii) 加入2-乙基己酸钠,甲酸甲酯和甲醇的混合物,然后加入甲酸甲酯;Iv) 结晶产物以获得无菌阿莫西林钠.

专利信息

专利号:WO-2020126584-A1
优先权日:2018-12-18
标 题 :Herbicidal combinations
发明人：KRAUS HELMUT; ZAGAR CYRILL; SEISER TOBIAS; BESSAI JOHANNES; DIMITRIADI TATJANA; BLAKEN MATTHEW; LANDES ANDREAS; GRIVEAU YANNICK; REID DANIELLE; VAN THIELEN NOCHA; BROWN JEFFREY; PETERS JDAVID
权利人:BASF AGROCHEMICAL PRODUCTS BV
摘要:The present invention relates to herbicidally active combinations comprising a herbicide A and at least one herbicide B, wherein the herbicide A is R-imazamox, any non-racemic mixture of R- imazamox and S-imazamox, wherein the proportion of R-imazamox is at least 80% by weight, or an agriculturally acceptable salt or ester thereof; and the at least one herbicide B is selected from the groups b1) to b15): b1)lipid biosynthesis inhibitors; b2)acetolactate synthase inhibitors (ALS inhibitors); b3)photosynthesis inhibitors; b4)protoporphyrinogen-IX oxidase inhibitors; b5)bleacher herbicides; b6)enolpyruvyl shikimate 3-phosphate synthase inhibitors (EPSP inhibitors); b7)glutamine synthetase inhibitors; b8)7,8-dihydropteroate synthase inhibitors (DHP inhibitors); b9)mitosis inhibitors; b10)inhibitors of the synthesis of very long chain fatty acids (VLCFA inhibitors); b11)cellulose biosynthesis inhibitors; b12)decoupler herbicides; b13)synthetic auxins; b14)auxin transport inhibitors; and b15)other herbicides.

专利号:CN-108905264-A
优先权日:2018-07-17
标 题:Application of continuous crystallization method in the synthesis of β-lactam antibiotics and continuous crystallization system

专利号:US-9416726-B2
优先权日:2012-11-20
标 题:Method for producing a gaseous fuel comprising hydrogen from kinetic and/or potential energy recovered from a vehicle powered by a four stroke diesel engine fitted with an engine braking mechanism and system useful to implement such method
发明人：BASTOS CARLOS MANUEL
权利人:WALDERSON MIAMI LLC
摘要:A method for producing a hydrogen gaseous fuel from kinetic and/or potential energy recovered from a vehicle powered by a four stroke Diesel engine fitted with a Jacobs engine brake during a deceleration stage. Such a method comprises the following steps: a) providing a preheated steam flow; b) providing a gas flow from at least one chemical species used as preheated carbon and hydrogen source; c) mixing the gas flow from at least one chemical species used as carbon and hydrogen source from step a) with the steam flow from step b); d) reacting the mixture from step c) in the catalytic bed of a reforming reactor, heated by high temperature air from the compression stage of the Diesel engine acting as engine brake upon deceleration, producing an outlet synthesis gas flow which contains hydrogen; e) causing water to condense in the outlet synthesis gas flow which contains hydrogen, producing a water-free synthesis gas flow, and f) storing the synthesis gas flow obtained at step e) in a reservoir for its subsequent use during an acceleration stage of the vehicle. A system useful to implement the method for recovering kinetic and/or potential energy from a vehicle powered by a four stroke Diesel engine fitted with a Jacobs engine brake during a deceleration stage.

专利号:US-11285169-B2
优先权日:2013-03-13
标题 :Methods for modulating chemotherapeutic cytotoxicity
发明人：ROBERTS DAVID D; SOTO PANTOJA DAVID R
权利人:US HEALTH
摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.